Metformin escape in prostate cancer by activating the PTGR1 transcriptional program through a novel super-enhancer

The therapeutic efficacy of metformin in prostate cancer (PCa) appears uncertain based on various clinical trials. Metformin treatment failure may be attributed to the high frequency of transcriptional dysregulation, which leads to drug resistance. However, the underlying mechanism is still unclear....

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Jianheng, Cai, Shanghua, Feng, Yuanfa, Li, Jinchuang, Cai, Zhiduan, Deng, Yulin, Liu, Ren, Zhu, Xuejin, Lu, Jianming, Zhuo, Yangjia, Liang, Yingke, Xie, Jianjiang, Zhang, Yanqiong, He, Huichan, Han, Zhaodong, Jia, Zhenyu, Zhong, Weide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427640/
https://www.ncbi.nlm.nih.gov/pubmed/37582751
http://dx.doi.org/10.1038/s41392-023-01516-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427640/
https://www.ncbi.nlm.nih.gov/pubmed/37582751
http://dx.doi.org/10.1038/s41392-023-01516-2

Ejemplares similares